Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

482.69 -2.13 (-0.44%)
Streaming Delayed Price Updated: 2:41 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Is Vertex Pharmaceuticals Gaining or Losing Market Support?
Via Benzinga
Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews
Via Benzinga
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval. 
Via Benzinga
Technical Signals Point to a Possible Breakout for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX).
Exploring VERTEX PHARMACEUTICALS INC's Technical Signals and Breakout Potential: Based on good technical signals, VERTEX PHARMACEUTICALS INC is potentially setting up for a breakout. 
Via Chartmill
Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
Via Benzinga
If I Could Buy Only 1 Growth Stock, This Would Be It
Via The Motley Fool
Is Vertex Pharmaceuticals Gaining or Losing Market Support?
Via Benzinga
Rattled by the Stock Market Sell-Off? These 3 Stocks Outperformed the S&P 500 During the Great Recession
Via The Motley Fool
Topics Economy Government Stocks
Exposures Economy Political Tariff
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?
The FDA is due to make an approval decision in mid-September for a key product from the top pharma company. 
Via Investor's Business Daily
Exposures Product Safety
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does Next
Via The Motley Fool
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack
Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
Via The Motley Fool
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
Via The Motley Fool
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Via Benzinga
3 Stocks With Ironclad Balance Sheets for Long-Term Stability
Check out these three stocks with balance sheets that have a case for being among the strongest in the entire stock market. 
Via MarketBeat
Topics Economy Supply Chain
Exposures Economy Supply Chain
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) is showing promising signs of setting up for a breakout.
Exploring VERTEX PHARMACEUTICALS INC's Technical Signals and Breakout Potential: Based on good technical signals, VERTEX PHARMACEUTICALS INC is potentially setting up for a breakout. 
Via Chartmill
Top 3 Health Care Stocks That May Keep You Up At Night In Q1
Via Benzinga
Nasdaq Correction: The 2 Smartest Stocks to Buy and Hold Forever
Via The Motley Fool
3 Reasons to Avoid VRTX and 1 Stock to Buy Instead
Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 1.6%. 
Via StockStory
Topics Stocks
Exposures US Equities
Where Will Vertex Pharmaceuticals Be in 10 Years?
Via The Motley Fool
Which S&P500 stocks are moving on Monday?
Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
3 Magnificent Growth Stocks to Buy in March
Via The Motley Fool
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales. 
Via Benzinga
Cannabis For Pain Relief: Scientists Develop New Compound Without Mind-Altering Effects — Alternative To Opioids?
New compound mimics natural molecule in cannabis plant, providing pain relief without addictive side effects. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Good technical signals and a possible breakout for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX).
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) has a strong technical rating of 9 out of 10, indicating a potential breakout. 
Via Chartmill
5 Top Stocks to Buy in March
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.